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Abstract
Several studies have established a link between cannabis and psychosis. However the causal role 
of cannabis in schizophrenia is still not clear. The aim of this paper is to summarise the literature 
pertaining to whether cannabis causes psychosis, whether the continued use of cannabis by patients 
with schizophrenia affects the course of the disease and its treatment, and whether it is possible to 
reduce cannabis use in patients who have a psychotic disorder.
Introduction
Cannabis is the most commonly used illicit drug in the world, the main age group misusing cannabis 
being 15-34 years of age. 75.5 million Europeans use cannabis at least once in their lifetime, and an 
estimated 23 million Europeans have used cannabis last year. Population survey data suggest that, 
on average, 31.6 % of young European adults (15–34 years) have ever used cannabis in their lifetime, 
while 12.6 % have used the drug in the last year. The data from the 2007 European School Survey 
project on alcohol and other drugs (ESPAD) and 2008 national school surveys reveal that the lifetime 
prevalence of cannabis use among 15 to 16-year-old school students in the United Kingdom ranged 
from 26 % to 32 % (1). 
Although there are more than 400 constituents in cannabis, Δ9THC is the main psychoactive 
cannabinoid. The home office cannabis potency study in 2008 showed that over the past decade the 
concentration of Δ9THC in cannabis has increased, particularly with increasing use of intensively-
grown cannabis (Skunk) (2). 
Association between cannabis misuse and psychosis
Various studies have shown that psychotic disorders are more common in patients who are dependent 
on cannabis or misuse cannabis significantly, compared to the general population. In a case-control 
study in the Netherlands, patients with first episode schizophrenia (59%) were found to misuse 
cannabis significantly more often compared to their siblings (21%) and general hospital controls 
(21%)(3). A number of epidemiological studies including the US National Epidemiological Catchment 
Area (ECA) study, the Australian National Survey of Mental Health and Well-Being (NSMHWB), and 
the Netherlands Mental Health Survey and Incidence Study (NEMESIS) all reported that psychotic 
disorders, including schizophrenia, were more common in individuals who used cannabis or were 
dependent on this drug, compared to non-users (4).
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a) Intoxication with cannabis (with or without presence of confusion) leading to psychotic symptoms
     that remit once exogenous cannabinoids are eliminated from the body.
b) Acute and transient psychotic disorder following cannabis use, where symptoms persist beyond a
     period reasonably attributable to the effects of exogenous cannabinoids.
 
c) Chronic psychosis, which persists after abstinence from cannabis.
Persistent cannabis misuse may be a risk-factor for serious mental illness such as schizophrenia or 
other chronic psychoses (5). The relationship between cannabis and persisting psychosis (b and 
c above) has been the focus of much study in recent years. Cannabis use has been consistently 
associated with increased incidence of psychosis, but it is very difficult to be certain that cannabis is a 
causative factor for schizophrenia. The association between cannabis and psychosis could also be due 
to bias, confounding, or reverse causality.
In this paper the authors addressed three questions. 
1) Does cannabis cause schizophrenia or other psychoses?
2) Does the continued use of cannabis by patients with schizophrenia affect the course of the disease
    and its treatment?
3) What interventions can reduce cannabis use in patients who have a psychotic disorder?
Does cannabis cause schizophrenia or other psychoses?
There has been much debate as to whether cannabis use increases the risk of developing chronic 
psychotic disorders such as schizophrenia. Andreasson & Allebeck (6) carried out a 15-year follow-up 
of 50087 Swedish conscripts who had self-reported on their cannabis use at age 18. They found that 
those who tried cannabis by age 18 years were 2.4 times more likely to develop schizophrenia than 
those who had not. The risk of developing schizophrenia was related in a dose–response way to the 
number of times cannabis had been used. Although they concluded that these findings supported 
a causal relationship between cannabis and schizophrenia, attention was drawn to a number of 
limitations in this study, relating to the possible effects of confounding by other drug misuse or 
personality traits of the individuals who used cannabis. To address these limitations, a follow-up 
study of the same cohort was conducted with an extended 27-year follow-up period that covered 
most of the risk period for the onset of psychotic disorders. The authors still concluded that cannabis 
use at baseline predicted an increased risk of schizophrenia during the follow-up period in a dose–
response manner. This relationship persisted after controlling for the effects of other drug use and 
other potential confounding factors, and remained after excluding cases occurring within 5-years of 
conscription, indicating that the association was very unlikely to have been due to ‘self-medication’, i.e. 
use of cannabis after onset of schizophrenia (7,8). 
 
The Dunedin birth cohort study (9) followed-up a general-population birth cohort of 1037 individuals 
born in Dunedin, New Zealand, in 1972-1973. Self-reports of cannabis use were obtained at ages 15 
and 18, and information was also obtained on self-reported psychotic symptoms at age 11, before the 
onset of cannabis use. At age 26 the cohort members were reassessed.  Cannabis use by age 15 was 
associated with an increased likelihood of meeting diagnostic criteria for schizophreniform disorder 
at age 26, with 10.3% meeting criteria compared to 3% for non-users. After controlling for age-11 
psychotic symptoms, the risk for adult schizophreniform disorder remained elevated, although it was 
attenuated. 
In the NEMESIS study (10), 4,045 subjects without any symptoms of psychosis at baseline were 
followed up at 1 year and 3 years. There was a dose response relationship between cannabis use 
at baseline and development of a psychotic disorder at follow-up, both before (OR for trend across 
4 categories of cannabis use = 4.0, 95% CI 2.2, 7.1) and after (adjusted OR = 3.5, 95% CI 1.6, 7.4) 
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adjustment for other drug use, ethnic group, marital status, educational level, urban living, and 
discrimination.
  
In the Early Developmental Stages of Psychopathology (EDSP) study (11), a prospective cohort study 
conducted in Germany, Keupper et al followed up 1923 individuals aged 14-24 at baseline, from 
the general population, for a period of 10 years. This was to determine whether use of cannabis in 
adolescence increases the risk for psychotic outcomes by affecting the incidence and persistence of 
psychotic symptoms in the general population. In individuals who had no reported lifetime psychotic 
symptoms and no reported lifetime cannabis use at baseline, cannabis use over the period from 
baseline to 3.5 years increased the risk of later incident psychotic symptoms over the period from 
3.5 – 8.4 years (adjusted odds ratio 1.9, 95% confidence interval 1.1 to 3.1; p=0.021). The incidence 
of psychotic symptoms over the period from baseline to 3.5 years was 31% in exposed individuals 
compared with 20% in non-exposed individuals; over the period from 3.5 – 8.4 years, these rates were 
14% and 8%, respectively. 
Moore et al. (12) carried out a systematic review of cannabis use and risk of psychotic or affective 
mental health outcomes and attempted to clarify whether cannabis can cause psychotic symptoms 
that persist beyond transient intoxication. Studies were included if they were longitudinal and 
population based, and only 7 studies were found that met these criteria. There was an increased risk of 
any psychotic outcome in individuals who had ever used cannabis (pooled adjusted odds ratio=1·41, 
95% CI 1·20–1·65). Findings were consistent with a dose-response effect, with greater risk in people 
who used cannabis most frequently (2·09, 1·54–2·84). Results of analyses restricted to studies of more 
clinically relevant psychotic disorders were similar. The authors examined to what extent results from 
each study could have been due to alternative (non-causal) explanations. A substantial confounding 
effect was present for both psychotic outcomes, but the authors nevertheless concluded that the 
evidence that cannabis use increased the risk of psychotic illnesses such as schizophrenia was strong 
enough that individuals using cannabis should be advised about this risk. 
Association between continued use of cannabis by patients with 
schizophrenia and the course of the disease and its treatment.
The EDSP study (11) also examined the persistence of psychotic symptoms in individuals who used 
cannabis. Continued use of cannabis increased the risk of persistent psychotic symptoms over the 
period from 3.5 – 8.4 years (OR 2.2, CI 1.2 to 4.2; p=0.016). The authors concluded that cannabis use is 
a risk factor for the development of incident psychotic symptoms and continued cannabis use might 
increase the risk for psychotic disorder by impacting on the persistence of symptoms.
In a study that spanned two different cultural settings, South London and Malta (13), psychotic 
patients abused substances much more than controls in both centres, although use of cannabis and 
other substances was much more widespread in the former. An extension of this study within the 
London sample tested the hypothesis that recent-onset psychotic patients who use cannabis would 
have psychotic symptoms that were more severe and more persistent than those who did not use 
cannabis. They carried out a 4-year follow-up study of a cohort of 119 patients with recent onset 
psychosis. Patients who continued to misuse cannabis had more positive symptoms and suffered 
from a more continuous illness at follow-up. They concluded that it is possible that psychotic patients 
who use cannabis are at a greater risk of a more continuous illness with more positive symptoms than 
those who do not.
Zammit et al. (14) carried out a systematic review of the effects of cannabis use on outcomes of 
psychotic disorders to examine whether research findings support clinical opinion that cannabis 
use leads to worse outcomes in people with psychosis, or whether this impression is confounded 
by other factors.  They reviewed 13 studies and examined rehospitalisation, readmission, measures 
of psychopathological symptoms, measures of treatment response and adherence to treatment as 
outcomes. Cannabis was consistently associated with increased relapse and rehospitalisation and with 
decreased treatment adherence in the studies that examined these outcomes, whereas associations 
with psychotic symptoms and other psychopathology scores were much more inconsistent.
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However, it was noted that few studies adjusted for baseline illness severity and most made no 
adjustment for alcohol or other potentially important confounders. It was therefore difficult to be 
confident that most of the associations reported were specifically due to cannabis. The authors 
concluded by suggesting that further research was needed to establish whether cannabis is harmful, 
what outcomes are particularly affected by cannabis use and how these effects occur. Furthermore, 
unlike determining whether or not cannabis use increases risk of rare disorders such as schizophrenia, 
studies that examine questions about the effects of cannabis on the outcome of people with psychosis 
are very feasible.
In a study that addressed a number of the limitations highlighted in the systematic review above, 
Foti et al. (15) assessed 229 patients with a schizophrenia spectrum disorder over 10 years of follow-
up after first psychiatric hospitalization. These patients were assessed five times: during the first 
admission and 6 months, 2 years, 4 years, and 10 years later. The aim was to examine the relationship 
between cannabis use and the course of the illness in schizophrenia. The authors rated cannabis use 
and psychiatric symptoms (psychotic, negative, disorganized, and depressive) at each assessment. 
Results showed the lifetime frequency of cannabis use was 66.2%, and survival analysis revealed that 
lifetime use was associated with an earlier onset of psychosis. Cannabis status was moderately stable, 
with tetrachoric correlation coefficients between waves ranging from 0.48 to 0.78. Mixed-effects 
logistic regression revealed that changes in cannabis use were associated with changes in psychotic 
symptoms over time even after gender, age, socioeconomic status, other drug use, antipsychotic 
medication use, and other symptoms were controlled for. The association between cannabis use and 
psychotic symptoms was bidirectional. The authors concluded that cannabis use is associated with an 
adverse course of psychotic symptoms in schizophrenia, and vice versa, even after taking into account 
other clinical, substance use, and demographic variables. 
Can cannabis use be reduced by psychoeducation in psychotic patients?
Most of the psychosocial interventions for cannabis misuse are based on motivational interviewing, 
cognitive behavioural therapy and relapse prevention. Maddock and Babbs (16) reviewed these 
studies and concluded that in adult patients, brief interventions were useful in helping to reduce or 
stop using cannabis. Agius and colleagues (17, 18) reported on the outcomes of early intervention 
service working for three years with patients who had suffered a first episode of psychosis. A group 
of patients in the early intervention (EI) service were compared with a group of patients who were 
treated by the community mental health teams. Patients in the early intervention group received more 
structured psycho-education about cannabis use and education in identifying the early warning signs. 
Patients in the CMHT group received routine care which involved outpatient reviews, treatment with 
antipsychotic medication and involvement of a care co-ordinator (only if necessary). Many patients in 
the CMHT group might not have received a systematic psycho-education regarding cannabis misuse. 
More patients in the EI group than in the CMHT group admitted to using illicit drugs at the beginning 
of the intervention. Less patients in the EI group than in the CMHT group were using illicit drugs 
especially cannabis at the end of three years, indicating that significantly more patients stopped using 
illicit drugs in the EI group than in the CMHT group (P=0.003). This might be because of more effective 
psychoeducation in the EI group. Given that cannabis use appears to increase relapse, delays the 
recovery and reduces the effectiveness of treatment for psychosis, interventions that can effectively 
reduce cannabis use in this group could be very important. Recent NICE guidance on the management 
of psychosis with coexisting substance misuse emphasizes the importance of psychoeducation and 
psychosocial interventions in this patient group (19).The psychoeducation provided within the EI 
group described above is a relatively simple and cheap intervention but it could make a substantial 
difference to morbidity at a population level if further studies support this as an effective approach to 
reducing cannabis use in individuals with psychotic disorders. 
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Conclusion
There is little dispute that cannabis intoxication can cause short-lived psychotic experiences 
(hallucinations, delusions and periods of thought disorder). Although uncertainty regarding causation 
is inevitable in the absence of RCTs, epidemiological studies support the belief that cannabis use 
leads to an increased risk of more severe and prolonged psychotic states. Further work in this area, 
including neuroimaging and animal model studies, as well as epidemiological studies focusing on the 
effects of more potent forms of cannabis, are on-going, and although beyond the scope of this review, 
also support a causal role of cannabis on psychotic outcomes. Current psychosocial interventions 
for reducing cannabis use should be based on the new NICE guidance relating to the management 
of psychosis with co-existing substance misuse.  Research to enable us to understand the reasons 
why patients at risk of psychosis use cannabis and why those who have already had an episode of 
cannabis-associated psychosis continue to use it, could be of particular value. The outcomes of such 
research might enable the psychosocial management of this complex group of patients to be more 
focussed and more effective. 
GP comment
What have I learned from this paper?
1. Despite the limitations in the research, there seems to be strong evidence that cannabis can
    increase the risk of developing schizophrenia.
2. The more the cannabis use, the higher the risk of developing schizophrenia seems to be.
3. Continued cannabis risk is associated with an increased risk of relapse and re-hospitalisation.
4. Knowing this information, I would very strongly recommend abstinence to anyone who has had
    a psychotic episode with cannabis and people at high risk of psychosis e.g. 1st degree relatives of 
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